Getinge Reports Impressive First Quarter of 2026 With Growth and Regulatory Success

Getinge's First Quarter 2026 Success

In the latest quarterly report, Getinge illustrated a remarkable performance in the first quarter of 2026, exceeding the already impressive numbers from the previous year. Mattias Perjos, the company's President and CEO, highlighted this achievement, stating that there was a significant organic growth in both net sales and order intake.

Net sales for the quarter showed a solid increase of 0.8%, trending positively despite a slight decline in the Acute Care Therapies sector, particularly in ventilator sales. There was a notable 3.9% rise in order intake, emphasizing the traction with customers. Although ventilators have seen a downturn due to previous market saturation, demand for consumables related to life-supporting ECLS therapy remained robust, contributing to steady growth from their established market leadership.

The Surgical Workflows division also marked a significant turnaround, with a double-digit increase in order intake attributed to growing demand across all product categories. Life Science products enjoyed a particularly strong start, achieving organic sales growth of 16%, bolstered by positive order intake rates across their offerings.

Financial Highlights

From a financial perspective, the adjusted EBITA margin was reported at 11.1%, with a projection of 12.6% had it not been for tariffs and currency fluctuations. This reflects an upward trend in underlying profitability, stemming from deliberate price adjustments and ongoing productivity enhancements. Furthermore, Getinge boasted a vigorous cash flow for the quarter, amounting to 842 million SEK, an almost fivefold jump from the previous year's 160 million SEK.

Perjos noted, "Maintaining a focus on cost control has placed us in a favorable position in a competitive landscape, ensuring we're set for future growth.” Indeed, his remarks suggest a strategic vision that encompasses adapting to market dynamics while prioritizing customer needs.

Additionally, Getinge celebrated a significant regulatory win by acquiring the CE mark for the Cardiohelp II, a state-of-the-art generation of their ECLS system. This achievement underscores their commitment to innovation, developed directly in response to customer feedback and needs in cardiovascular surgery. The Intergard Synergy antimicrobial vascular graft's receipt of EU MDR approval further showcases their advancements in medical technology, which are pivotal in establishing their foothold within Europe.

"We are reinforcing our position in categories that customers value. This gives us considerable optimism about our prospects for the future," Perjos added, expressing confidence amid a climate of geopolitical uncertainty that has left many companies re-evaluating forecasts.

Despite potential macroeconomic challenges, Getinge has upheld its target for organic sales growth between 3% and 5% for the year 2026. As global markets shift and adapt to unforeseen economic scenarios, such resolute forecasts reflect the company’s resilience and proactive customer engagement strategies.

Conference Call Details

In conjunction with these findings, Getinge will host a conference call on April 21 from 13:00 to 14:00 CEST, featuring insights from its leadership. Participants must register to receive access details, allowing for interactive dialogue among investors and analysts regarding the company’s growth strategies and product developments.

As Getinge navigates the complexities of the medical device sector, its promise for sustained growth and pioneering advancements positions it favorably within a broad spectrum of stakeholders, including healthcare providers and investors alike. The report not only showcases achievements but also heralds a significant period for the company, driven by innovation and a firm understanding of market needs.

With a workforce of around 12,000 individuals and a presence in over 135 countries, Getinge continues to innovate to ensure that every community has access to the best possible care, confirming its role as a leader within the global healthcare landscape.